# Latvia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Latvia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Latvia (LVA)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $329.0M
- Products: 33
- Buyer markets: 27
- Average CAGR: +33.8%
- Global sector size: $723.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $183.8M | $116.4B | +23.3% | 22 | +0.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $151.5B | $7.2M | $62.3B | +21.9% | 14 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $31.3B | $206.7K | $50.5B | -1.3% | 6 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $103.6K | $23.0B | +9.4% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $24.8B | $828.4K | $18.3B | +25.9% | 9 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $29.2K | $16.8B | -0.8% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $11.9B | $189.6K | $12.0B | +4.1% | 3 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $20.9B | $1.1M | $11.6B | +57.1% | 5 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $13.7B | $2.3M | $10.4B | +18.1% | 6 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $434.3K | $8.5B | +29.8% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $3.1M | $8.0B | +25.7% | 4 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $8.9B | $18.3 | $7.2B | -21.4% | 3 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.5B | $2.5K | $7.1B | +17.6% | 2 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $33.6 | $6.7B | +59.9% | 1 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $6.0M | $6.4B | -7.6% | 3 | +0.1% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $16.7M | $6.3B | +34.3% | 3 | +0.1% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $44.0K | $6.1B | +25.8% | 3 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $8.0B | $102.8M | $6.0B | +45.6% | 2 | +1.1% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $400.0K | $5.9B | -1.1% | 2 | +0.0% |
| HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $265.6 | $5.1B | +26.7% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $3.4M | $4.1B | +18.3% | 2 | +0.1% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $2.8K | $3.8B | -19.1% | 2 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.3B | $5.0 | $2.6B | -7.5% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $3.8K | $2.1B | -24.7% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $176.5K | $2.0B | +7.5% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $53.3K | $1.7B | +1933.1% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $24.1 | $1.4B | +2.1% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $4.9K | $1.4B | -7.5% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $887.8 | $1.2B | +4.4% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $29.2 | $1.1B | -4.6% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $23.7 | $1.1B | -49.1% | 1 | +0.0% |
| HS 290250 - Cyclic hydrocarbons: styrene | $768.8M | $29.7K | $1.1B | -0.3% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $3.4K | $1.0B | -6.6% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $110.2B calculated opportunity across 14 products.
- Slovenia (SVN): $44.0B calculated opportunity across 7 products.
- Germany (DEU): $37.0B calculated opportunity across 11 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Belgium (BEL): $31.7B calculated opportunity across 7 products.
- Italy (ITA): $25.1B calculated opportunity across 5 products.
- Netherlands (NLD): $20.5B calculated opportunity across 6 products.
- China (CHN): $19.7B calculated opportunity across 7 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Spain (ESP): $11.6B calculated opportunity across 6 products.
- Canada (CAN): $9.0B calculated opportunity across 5 products.
- Mexico (MEX): $8.2B calculated opportunity across 5 products.

## Growth stars

- HS 284390: +1933.1% average CAGR, $1.7B calculated opportunity.
- HS 300339: +59.9% average CAGR, $6.7B calculated opportunity.
- HS 300212: +57.1% average CAGR, $11.6B calculated opportunity.
- HS 382600: +45.6% average CAGR, $6.0B calculated opportunity.
- HS 382200: +34.3% average CAGR, $6.3B calculated opportunity.
- HS 293499: +29.8% average CAGR, $8.5B calculated opportunity.
- HS 293319: +26.7% average CAGR, $5.1B calculated opportunity.
- HS 382499: +25.9% average CAGR, $18.3B calculated opportunity.
- HS 293590: +25.8% average CAGR, $6.1B calculated opportunity.
- HS 330499: +25.7% average CAGR, $8.0B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.4B calculated opportunity.
- HS 300215: 14 buyer markets, $62.3B calculated opportunity.
- HS 382499: 9 buyer markets, $18.3B calculated opportunity.
- HS 293719: 6 buyer markets, $50.5B calculated opportunity.
- HS 300439: 6 buyer markets, $10.4B calculated opportunity.
- HS 300212: 5 buyer markets, $11.6B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 293359: 3 buyer markets, $23.0B calculated opportunity.
- HS 293399: 3 buyer markets, $16.8B calculated opportunity.
- HS 300220: 3 buyer markets, $12.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.